Proteomics derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma.

Proteomics derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma.

Publication date: Apr 12, 2019

Ovarian carcinomas are a group of distinct diseases classified by histotypes. As histotype-specific treatment evolves, accurate classification will become critical for optimal precision medicine approaches.

To uncover differences between the two most common histotypes – high-grade serous (HGSC) and endometrioid carcinoma (EC) – we performed label-free quantitative proteomics on freshly frozen tumour tissues (HGSC, n=10; EC, n=10). Eight candidate protein biomarkers specific to EC were validated by immunohistochemistry using tissue microarrays representing 361 cases of either EC or HGSC.

Over 500 proteins were differentially expressed (p

Postovit, L.M., Dieters-Castator, D.Z., Rambau, P.F., Kelemen, L.E., Siegers, G.M., Lajoie, G.A., and K”obel, M. Proteomics derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma. 04413. 2019 Clin Cancer Res.

Concepts Keywords
Biomarker Proteomics
Biomarkers Proteomics
Carcinoma Carcinoma
Carcinomas Ovarian cancer
Immunohistochemistry Biomarker
Microarrays Oncology
Ovarian Carcinoma RTT
Proteomics Gynaecology
Serous Gynaecological cancer
Tumour Clinical medicine
Anatomical pathology
Medicine
Branches of biology
Tumour

Semantics

Type Source Name
disease DOID endometrioid carcinoma
disease MESH endometrioid carcinoma
disease MESH carcinomas
disease DOID ovarian carcinoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *